Risk of Incident Psychosis and Mania With Prescription Amphetamines
- PMID: 39262211
- DOI: 10.1176/appi.ajp.20230329
Risk of Incident Psychosis and Mania With Prescription Amphetamines
Abstract
Objective: Amphetamine prescribing has increased in the United States in recent years. Previous research identified an increased risk of incident psychosis with prescription amphetamines. The purpose of this study was to examine the impact of dose levels of prescription amphetamines on the risk of this rare but serious adverse outcome.
Methods: A case-control study using electronic health records was conducted to compare the odds of incident psychosis or mania with past-month exposure to prescription amphetamines. Case subjects were patients ages 16-35 hospitalized at McLean Hospital for incident psychosis or mania between 2005 and 2019. Control subjects were patients with an initial psychiatric hospitalization for other reasons, most commonly depression and/or anxiety. Amphetamine doses were converted to dextroamphetamine equivalents and divided into terciles. Secondary analyses evaluated the odds of psychosis or mania with methylphenidate use.
Results: Among 1,374 case subjects and 2,748 control subjects, the odds of psychosis and mania were increased for individuals with past-month prescription amphetamine use compared with no use (adjusted odds ratio=2.68, 95% CI=1.90-3.77). A dose-response relationship was observed; high doses of amphetamines (>30 mg dextroamphetamine equivalents) were associated with 5.28-fold increased odds of psychosis or mania. Past-month methylphenidate use was not associated with increased odds of psychosis or mania compared with no use (adjusted odds ratio=0.91, 95% CI=0.54-1.55).
Conclusions: Although use of hospitalized control subjects excludes individuals with less severe disease, leading to selection bias, the study results suggest that caution should be exercised when prescribing high doses of amphetamines, with regular screening for symptoms of psychosis or mania.
Keywords: Bipolar and Related Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Stimulants; Substance-Related and Addictive Disorders.
Conflict of interest statement
Dr. Moran is employed by Sage Therapeutics. Dr. Perlis has served as a scientific adviser for Alkermes, Belle Artificial Intelligence, Burrage Capital, Circular Genomics, Genomind, Mila Health, Psy Therapeutics, Swan AI Studios, and Vault Health. Dr. Ongur has received honoraria from Boehringer Ingelheim, Guggenheim LLC, and Neumora for scientific presentations. The other authors report no financial relationships with commercial interests.
Similar articles
-
Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.N Engl J Med. 2019 Mar 21;380(12):1128-1138. doi: 10.1056/NEJMoa1813751. N Engl J Med. 2019. PMID: 30893533 Free PMC article.
-
Prescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study.J Clin Psychopharmacol. 2015 Dec;35(6):667-71. doi: 10.1097/JCP.0000000000000406. J Clin Psychopharmacol. 2015. PMID: 26485338 Free PMC article.
-
Psychosis Risk With Prescription Amphetamine.Am J Psychiatry. 2024 Oct 1;181(10):856-857. doi: 10.1176/appi.ajp.20240732. Am J Psychiatry. 2024. PMID: 39350617 No abstract available.
-
Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.Clin Neuropharmacol. 2010 Jul;33(4):204-6. doi: 10.1097/WNF.0b013e3181e29174. Clin Neuropharmacol. 2010. PMID: 20571380 Review.
-
Amphetamine psychosis: a model for studying the onset and course of psychosis.Med J Aust. 2009 Feb 16;190(S4):S22-5. doi: 10.5694/j.1326-5377.2009.tb02370.x. Med J Aust. 2009. PMID: 19220169 Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
